Nation's #1 Respiratory Hospital Enters Agreement to Co-Promote IgE Blo...( - Partnership Underscores Role of ...),Health

- Partnership Underscores Role of Allergy Testing in Improving Asthma

Outcomes -

DENVER, Oct. 31 /PRNewswire/ -- National Jewish Health announced today that it has entered a co-promotion agreement with Phadia, US Inc. to build recognition of the important role allergy testing plays in the diagnosis and treatment of asthma and other respiratory diseases. Under the agreement, National Jewish Health will help create educational programs, activities and literature to promote to pulmonologists the value of understanding allergy in the diagnosis and management of patients with respiratory diseases. National Jewish will discuss available methodologies for in-office testing for allergies in these patients. Phadia currently has a product for such testing in the office, ImmunoCAP Rapid, which is currently under review by the United States Food and Drug Administration (FDA). Phadia anticipates FDA clearance by the end of the first quarter of 2009.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080711/DC27335LOGO)

"National Jewish Health is devoted to combating the uncontrolled asthma epidemic in the United States, and access in our clinics and regional sites to the latest technology will further accelerate our success," said David Tinkelman, MD, Vice President of Health Initiatives at National Jewish. "Our expertise will be invaluable in creating educational opportunities for this important part of the assessment of patients with respiratory diseases."

National Jewish will develop educational services and materials emphasizing the importance and utility of testing patients for allergy in the office setting for pulmonologists. Those services include many elements, but importantly a website for both consumers and physicians who can seek advice and assistance for treatment and avoidance options.

According to the American Ac
'/>"/>